Skip to main content
300 Collins St Melbourne hello@pivot.net
Login Signup
Home Home

Main navigation

  • About
    • Senior Management
    • Leadership
    • Board of Directors
    • Advisors
    • Contact
  • Research & Development
    • Innovation Engine
    • Therapeutic Focus
    • Development Strategy
    • Scientific Presentations
  • Pipeline
    • RMC-4630 (SHP2)
    • RMC-5552 (mTORC1/4EBP1)
    • SOS1
    • RAS(ON) Inhibitors
    • EXPANDED ACCESS POLICY
  • Investors
  • Careers

Bi-steric mTORC1-selective Inhibitors activate 4EBP1 reversing MYC-induced tumorigenesis and synergize with immunotherapy

February 5, 2022

Wadie D. Mahauad-Fernandez, Yu Chi Yang, Ian Lai, Jangho Park, Lilian Yao, James W. Evans, G. Leslie Burnett, Adrian Gill, Jacqueline A. M. Smith, Mallika Singh, Dean W. Felsher

 

bioRxiv

 

Read full article
Return to Media Home

Latest Scientific Presentations

Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors
Enhancement of anti-tumor immunity in immunogenic and immune-refractory RAS mutant tumors with tri-complex RAS(ON) inhibitors
The Bi-steric mTORC1-Selective Inhibitor RMC-5552 in Tumors with Activation of mTOR Signaling: Preclinical Activity in Combination with RAS(ON) Inhibitors in RAS-Addicted Tumors, and Initial Clinical Findings from A Single Agent Phase 1/1b Study
RMC-6291, a Next-Generation Tri-Complex KRAS-G12C(ON) Inhibitor, Outperforms KRAS-G12C(OFF) Inhibitors in Preclinical Models of KRAS-G12C Cancers
Translating Frontier Oncology Targets to Outsmart RAS-Addicted Cancers
© Revolution Medicines, Inc.  |  700 Saginaw Drive, Redwood City, CA 94063
CCPA Notice | Privacy Policy
Get in touch with us